人类胚胎干细胞法律规制的路径研究  

Research on Legal Regulation of Human Embryonic Stem Cells

作　　者：寿天 SHOU Tian(Law School of Shanghai Maritime University,Shanghai 201306,China)

机构地区：[1]上海海事大学法学院,上海201306

出　　处：《医学与法学》2024年第2期81-85,共5页Medicine and Jurisprudence

基　　金：教育部2021年度哲学社会科学研究重大课题攻关项目“民法典民族性表达与制度供给研究”(项目编号:21JZD033)阶段性成果。

摘　　要：人类胚胎干细胞具有很高的研究和临床应用价值,而目前我国关于人类胚胎干细胞研究的法规还在探索阶段,故尚存在临床研究备案制不足以防范伦理风险、对科研机构及其工作人员法律责任的认定不够细化、有关捐赠者与受赠者的知情同意规定不完善等问题;由剖析英、美、德等对人类胚胎干细胞研究的法律规范,对我国人体胚胎干细胞研究之科学立法原则、机构准入、科研机构及其工作人员法律责任和相关人员知情同意书等提出有针对性的完善性建议。Human embryonic stem cells have high research and clinical application value,but at present,China's regulations on human embryonic stem cell research are still in the exploratory stage,so there are still problems such as insufficient clinical research record system to prevent ethical risks,insufficient identification of legal responsibilities of scientific research institutions and their staff,and imperfect provisions on informed consent of donors and recipients.By analyzing the legal norms of human embryonic stem cell research in the United Kingdom,the United States and Germany,this paper puts forward some suggestions on the principles of scientific legislation,institutional access,legal responsibility of scientific research institutions and their staff,and informed consent of relevant personnel in China.

关 键 词：人类胚胎 干细胞研究 法律规制 

分 类 号：R-052[医药卫生]